Background: Multiple myeloma (MM) with 1q21 gains invariably has a poor prognosis. Many recent studies have reported the relationship between micro (mi)RNA expression and MM prognosis. However, there is little information on the association between miRNA alterations and 1q21 gains. Methods: We compared the miRNA expression profiles of MM with 1q21 gains and MM with normal fluorescence in situ hybridisation (FISH) by gene expression array. Differentially expressed miRNAs were identified using Affymetrix TAC software. Thresholds were defined as a false discovery rate <0.05, p value <0.05, and n-fold change >2. Results: Six miRNAs (let-7f-5p and -7g-5p, and miR-29a-3p, -29b-1-5p, -331-3p, and -223-3p) were downregulated and 4 (miR-30e-5p, -17-3p, -18b-5p, and -19a-3p) were upregulated in MM with 1q21 gains relative to MM with normal FISH. Conclusions: The identified set of miRNAs can serve as biomarkers for distinguishing MM with 1q21 gains from MM with normal FISH.

Keywords:
Multiple myeloma, Micro RNA, 1q21, Fluorescence in situ hybridisation
1.
Kapoor P, Fonseca R, Rajkumar SV, Sinha S, Gertz MA, Stewart AK, Bergsagel PL, Lacy MQ, Dingli DD, Ketterling RP, Buadi F, Kyle RA, Witzig TE, Greipp PR, Dispenzieri A, Kumar S: Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies. Mayo Clin Proc 2010; 85: 532–537.
2.
Saki N, Abroun S, Hajizamani S, Rahim F, Shahjahani M: Association of chromosomal translocation and miRNA expression with the pathogenesis of multiple myeloma. Cell J 2014; 16: 99–110.
3.
Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San MJ: Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884–892.
4.
Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, Zhan F: Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010; 1: 22–33.
5.
Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A: Micrornas in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2012; 12: 823.
6.
Abdi J, Jian H, Chang H: Role of micro-RNAs in drug resistance of multiple myeloma. Oncotarget 2016; 7: 60723–60735.
7.
Bong I, Ng CC, Baharuddin P, Zakaria Z: MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy. Genes Genomics 2017; 39: 533–540.
8.
Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ: Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol 2013; 162: 348–359.
9.
Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las RJ, Ticona FV, Ferminan E, Martin-Jimenez P, Chillon C, Risueno A, Hernandez JM, Garcia-Sanz R, Gonzalez M, San MJ: Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia 2010; 24: 629–637.
10.
Saki N, Abroun S, Hajizamani S, Rahim F, Shahjahani M: Association of chromosomal translocation and miRNA expression with the pathogenesis of multiple myeloma. Cell J 2014; 16: 99–110.
11.
Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403: 901–906.
12.
Nair VS, Maeda LS, Ioannidis JP: Clinical outcome prediction by microRNAs in human cancer: a systematic review. J Natl Cancer Inst 2012; 104: 528–540.
13.
Roush S, Slack FJ: The let-7 family of micro-RNAs. Trends Cell Biol 2008; 18: 505–516.
14.
Selvanayagam P, Blick M, Narni F, van Tuinen P, Ledbetter DH, Alexanian R, Saunders GF, Barlogie B: Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood 1988; 71: 30–35.
15.
Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, Roccaro AM, Daley GQ, Ghobrial IM: The lin28b/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia 2017; 31: 853–860.
16.
Kollinerova S, Vassanelli S, Modriansky M: The role of miR-29 family members in malignant hematopoiesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014; 158: 489–501.
17.
Zhang YK, Wang H, Leng Y, Li ZL, Yang YF, Xiao FJ, Li QF, Chen XQ, Wang LS: Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. Biochem Biophys Res Commun 2011; 414: 233–239.
18.
Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG, Osieka R: DNA methylation changes in multiple myeloma. Leukemia 2004; 18: 1687–1692.
19.
Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R: Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma 2013; 54: 189–191.
20.
Kang HS, Lee BS, Yang Y, Park CW, Ha HJ, Pyun KH, Choi I: Roles of protein phosphatase 1 and 2a in an IL-6-mediated autocrine growth loop of human myeloma cells. Cell Immunol 1996; 168: 174–183.
21.
Mitsuhashi S, Shima H, Tanuma N, Sasa S, Onoe K, Ubukata M, Kikuchi K: Protein phosphatase type 2A, PP2A, is involved in degradation of gp130. Mol Cell Biochem 2005; 269: 183–187.
22.
Olive V, Jiang I, He L: mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010; 42: 1348–1354.
23.
Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T: Targeted deletion reveals essential and overlapping functions of the mir-17 through 92 family of miRNA clusters. Cell 2008; 132: 875–886.
24.
Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503–508.
25.
Navarro A, Diaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, Magnano L, Rosinol L, Monzo M, Blade J, Fernandez DLC: A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. Oncotarget 2015; 6: 1874–1883.
26.
Feng DD, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH, Chen YQ: Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. J Cell Mol Med 2011; 15: 2164–2175.
27.
Xiang T, Hu AX, Sun P, Liu G, Liu G, Xiao Y: Identification of four potential predicting miRNA biomarkers for multiple myeloma from published datasets. Peer J 2017; 5:-e2831.
28.
Liu K, Li G, Fan C, Diao Y, Wu B, Li J: Increased expression of microRNA-221 in gastric cancer and its clinical significance. J Int Med Res 2012; 40: 467–474.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.